Last reviewed · How we verify
iron and vitamin a
Iron and Vitamin A, marketed by Chengdu Maternal and Children's Health Care Hospital, is a nutritional supplement with a key composition patent expiring in 2028. The drug leverages its established presence in the market to address deficiencies in target populations. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | iron and vitamin a |
|---|---|
| Sponsor | Chengdu Maternal and Children's Health Care Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Iron and Immune Response to Vaccine (IRONMUM) (NA)
- Effectiveness and Acceptability of LISEFEX® (Liposomal Iron With Vitamin C and Fiber) in People With Iron Deficiency Anemia.
- Child Health, Agriculture and Integrated Nutrition (NA)
- Patient Blood Management in Cardiac Surgery (NA)
- Feasibility or Oral Lactoferrin to Prevent Iron Deficiency Anemia in Obese Pregnancy (NA)
- Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy (NA)
- Chemo Brain Prehab Project (NA)
- Dietary Strategy to Tackle Sarcopenia in Early Elderly Subjects (FOOP-Sarc) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iron and vitamin a CI brief — competitive landscape report
- iron and vitamin a updates RSS · CI watch RSS
- Chengdu Maternal and Children's Health Care Hospital portfolio CI